GlaxoSmithKline and Novartis sign $25 billion worth of drug deals
Thinkstock


Two of the world's biggest drugmakers, Britain's GlaxoSmithKline and Switzerland's Novartis, announced a complex hodgepodge of deals worth at least $25 billion on Tuesday. The main components:
* Novartis agreed to buy Glaxo's oncology business for between $14.5 billion and $16 billion* Glaxo is buying Novartis' vaccine business for between $5.3 billion and $7.1 billion* The two companies are combining their consumer health (over-the-counter) divisions, with Glaxo taking 63.5 percent of the joint venture* Eli Lilly will purchase Novartis' animal health unit for about $5.4 billion
The transactions will let Novartis focus on high-margin businesses like cancer drugs while Glaxo boosts its position in consumer goods and the low-margin, high-volume vaccine market. But the pharmaceutical giants aren't the only drugmakers making high-stakes deals. The Wall Street Journal says the $25 billion worth of transactions cap a 24-hour period where "deals worth, conservatively, $65 billion" were announced, not counting Pfizer's unsolicited $101 billion offer to buy Britain's AstraZeneca.
"The Novartis-Glaxo deal and rumors about a potential AstraZeneca acquisition by Pfizer are giving the pharma sector a decent run this morning," Danish strategist Witold Bahrke tells Bloomberg News. "It's also fueling further M&A expectations."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Taz Sarhane's mallard with pine nut sauce and boulangère potatoes
The Week Recommends Bold duck, crispy potatoes and silky pine-nut sauce come together in this earthy yet refined dish
-
Cambodian pork and rice recipe
The Week Recommends This street-food dish is traditionally eaten for breakfast, but makes a delicious dinner, too
-
Xiao Zintong: China's controversial snooker champion
In the Spotlight The 28-year-old was implicated in the sport's biggest match-fixing scandal before coming back from suspension to take the world title
-
Shakespeare not an absent spouse, study proposes
speed read A letter fragment suggests that the Shakespeares lived together all along, says scholar Matthew Steggle
-
New Mexico to investigate death of Gene Hackman, wife
speed read The Oscar-winning actor and his wife Betsy Arakawa were found dead in their home with no signs of foul play
-
Giant schnauzer wins top prize at Westminster show
Speed Read Monty won best in show at the 149th Westminster Kennel Club dog show
-
Beyoncé, Kendrick Lamar take top Grammys
Speed Read Beyoncé took home album of the year for 'Cowboy Carter' and Kendrick Lamar's diss track 'Not Like Us' won five awards
-
The Louvre is giving 'Mona Lisa' her own room
Speed Read The world's most-visited art museum is getting a major renovation
-
Honda and Nissan in merger talks
Speed Read The companies are currently Japan's second and third-biggest automakers, respectively
-
Taylor Swift wraps up record-shattering Eras tour
Speed Read The pop star finally ended her long-running tour in Vancouver, Canada
-
Drake claims illegal boosting, defamation
Speed Read The rapper accused Universal Music of boosting Kendrick Lamar's diss track and said UMG allowed him to be falsely accused of pedophilia